Retatrutide Beats Ozempic Head-to-Head, Doubling Weight Loss in Phase 3
LLY sits 57% above its 52-week low of $809.63.
Summary
Lilly's triple-agonist retatrutide beat a 2 mg dose of Novo's Ozempic in a late-stage head-to-head trial in type 2 diabetes, cutting A1C by 2.2% versus 1.8% at 80 weeks. Patients on the 9 mg dose lost an average of 44.3 pounds and the 12 mg dose 47.4 pounds, against 20.9 pounds on Ozempic — more than double. Lilly notes 2 mg is the highest approved Ozempic dose, so the comparison is against Novo's best available diabetes label rather than its obesity dose. This is the clearest efficacy edge yet in the obesity/GLP-1 race and lands on top of an already strong 2026 run: Q2 revenue rose 48% to $23B, EloraTZP showed 23.3% weight loss at 48 weeks in September, and oral Foundayo posted cardiovascular outcomes in ACHIEVE-4. Retatrutide still needs approval; the data strengthens the case for the next-gen franchise as Lilly trades near its 52-week high.
At the time of this announcement, LLY was trading at $1,273.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.2T. The 52-week trading range was $809.63 to $1,321.21. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.